DNA
Ginkgo Bioworks Holdings
10.30$
+19.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -37.3% | +9.2% | +48.1% | +58.4% | -50.8% | +10.2% | +2.7% | -21.7% | -14.0% | -41.7% | +3.5% | – | |
| – | -4.5% | +39.2% | +49.1% | -27.2% | -3.7% | +25.2% | +23.0% | -13.6% | -163.7% | – | -89.2% | – | |
| – | -42.0% | +2.1% | +47.8% | +86.1% | -56.7% | +6.0% | -4.1% | -25.1% | +59.6% | -91.4% | +415.4% | – | |
| – | -25.3% | +16.6% | -1.6% | -42.6% | -0.8% | -7.1% | -24.7% | +29.9% | -27.7% | -0.4% | -7.4% | – | |
| – | +8.8% | -21.2% | -5.7% | -21.1% | +9.6% | -14.4% | -11.8% | +3.9% | +2.4% | -17.8% | -18.6% | – | |
| – | -38.4% | +0.2% | +28.4% | -49.4% | +2.7% | -9.1% | -19.9% | +15.7% | -3.2% | -33.3% | +2.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +512.9% | -297.4% | – | – | -421.6% | – | -64,400.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.